Colorectal Cancer Screening for Average-Risk North Americans: An Economic Evaluation by Heitman, Steven J. et al.
Colorectal Cancer Screening for Average-Risk North
Americans: An Economic Evaluation
Steven J. Heitman
1,2, Robert J. Hilsden
1,2, Flora Au
1, Scot Dowden
1,3, Braden J. Manns
1,2,4*
1The Department of Medicine, University of Calgary, Alberta, Canada, 2The Department of Community Health Sciences, University of Calgary, Alberta, Canada, 3Alberta
Health Services - Cancer Care, Alberta, Canada, 4Libin Cardiovascular Institute, University of Calgary, Alberta, Canada
Abstract
Background: Colorectal cancer (CRC) fulfills the World Health Organization criteria for mass screening, but screening uptake
is low in most countries. CRC screening is resource intensive, and it is unclear if an optimal strategy exists. The objective of
this study was to perform an economic evaluation of CRC screening in average risk North American individuals considering
all relevant screening modalities and current CRC treatment costs.
Methods and Findings: An incremental cost-utility analysis using a Markov model was performed comparing guaiac-based
fecal occult blood test (FOBT) or fecal immunochemical test (FIT) annually, fecal DNA every 3 years, flexible sigmoidoscopy
or computed tomographic colonography every 5 years, and colonoscopy every 10 years. All strategies were also compared
to a no screening natural history arm. Given that different FIT assays and collection methods have been previously tested,
three distinct FIT testing strategies were considered, on the basis of studies that have reported ‘‘low,’’ ‘‘mid,’’ and ‘‘high’’ test
performance characteristics for detecting adenomas and CRC. Adenoma and CRC prevalence rates were based on a recent
systematic review whereas screening adherence, test performance, and CRC treatment costs were based on publicly
available data. The outcome measures included lifetime costs, number of cancers, cancer-related deaths, quality-adjusted
life-years gained, and incremental cost-utility ratios. Sensitivity and scenario analyses were performed. Annual FIT, assuming
mid-range testing characteristics, was more effective and less costly compared to all strategies (including no screening)
except FIT-high. Among the lifetimes of 100,000 average-risk patients, the number of cancers could be reduced from 4,857
to 1,782 and the number of CRC deaths from 1,393 to 457, while saving CAN$68 per person. Although screening patients
with FIT became more expensive than a strategy of no screening when the test performance of FIT was reduced, or the cost
of managing CRC was lowered (e.g., for jurisdictions that do not fund expensive biologic chemotherapeutic regimens), CRC
screening with FIT remained economically attractive.
Conclusions: CRC screening with FIT reduces the risk of CRC and CRC-related deaths, and lowers health care costs in
comparison to no screening and to other existing screening strategies. Health policy decision makers should consider
prioritizing funding for CRC screening using FIT.
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As the fourth most common cancer and second-leading cause of
cancer death among men and women [1], colorectal cancer (CRC)
is an important health issue. CRC fulfills the World Health
Organization (WHO) criteria for mass screening [2], and existing
clinical practice guidelines recommend that average risk individ-
uals begin screening at age 50 [3–6]. A variety of CRC screening
modalities are available, including stool-based tests and radiolog-
ical and endoscopic examinations of the colon. Colonoscopy has
high sensitivity for identifying adenomas and cancer and permits
the removal of polyps during a screening examination [7].
However, the risk of complications (including bleeding, perfora-
tion, and death) and barriers to access including limited
availability and high patient-borne costs [8] diminish its appeal.
The guaiac-based fecal occult blood tests (FOBTs) have been
shown in randomized controlled trials (RCTs) to reduce CRC
mortality [9–11]. However, FOBT has low sensitivity for
identifying colorectal neoplasia, in particular adenomas. The fecal
immunochemical tests (FITs) have improved test performance
characteristics [12] and potential to improve participation rates
compared to FOBT and flexible sigmoidoscopy [13]. A third type
of stool test, based on the detection of DNA shed by neoplastic
tissue (fecal DNA) is also available [14,15]. Lastly, computed
tomographic colonography (CTC) or ‘‘virtual’’ colonoscopy is a
promising new modality [6]. Although recent studies [16–18] have
shown CTC to rival colonoscopy in detecting advanced adenomas
and CRC, CTC is expensive, requires a full colonic preparation,
and the available cost-effectiveness data have been contradictory
[19–21].
In light of the rapidly rising costs of chemotherapy for CRC
[22], and evidence that CRC mortality can be reduced by
screening [9–11], population-based screening programs for
average risk individuals are being considered in several countries.
In the absence of firm comparative evidence to guide the selection
of any one modality, the practice in some jurisdictions has been to
recommend choice among the available screening options [3–5].
However, some countries do not support population-based CRC
screening and many with organized programs do not offer choice
[23]. Given the varied test performance characteristics and the
significant differences in costs and resources associated with each,
health care decision makers should consider the results of cost-
effectiveness analyses when deciding whether or not to offer
screening and in selecting the most appropriate screening
modality.
There have been several previous economic analyses of CRC
screening [24], though recent studies have failed to consider all
potentially relevant strategies including CTC [25,26] and FIT
[27]. Furthermore, a wide range of FIT test performance has been
reported, the impact of which requires further exploration in cost-
effectiveness analyses. Finally, many studies have not considered
current CRC treatment costs, nor the different nonmedical costs
between CRC screening strategies, both of which may be
important. Given these limitations, we performed a full economic
evaluation of all relevant CRC screening modalities in North
America, and present our results in a transparent fashion to assist
medical decision makers.
Methods
Overview
An incremental cost-utility analysis was performed comparing
the following CRC screening modalities: guaiac-based FOBT,
FIT, fecal DNA, colonoscopy, flexible sigmoidoscopy, and CTC.
These modalities were compared to each other and to a no
screening natural history arm among average-risk individuals,
aged 50 to 75 y. Two average-risk age-stratified patient cohorts
were simultaneously modelled: people aged 50–64 and 65–75. In
the base case, screening was assumed to continue from age 50–75,
but the analysis continued over the lifetime of the cohorts. Average
risk was defined as asymptomatic individuals with no personal or
family history of CRC or adenomatous polyps and no history of
preexisting medical conditions known to increase the risk of CRC
(e.g., inflammatory bowel disease).
Although we acknowledge that many jurisdictions are already
committed to CRC screening, we included a no screening strategy
given that, despite widespread screening recommendations, the
majority of individuals are not being screened [28]. In the base
case analysis, costs were those relevant to a publicly funded health
care system and included patient time and travel costs in keeping
with recent guidelines [29]. Consistent with contemporary
guidelines and the perspective of the publicly funded health care
system, costs resulting from lost productivity were not considered
[29]. Given the impact of CRC on both quantity and quality of
life, health benefits were measured in quality-adjusted life-years
(QALYs) gained over a lifetime horizon. Future costs and benefits
were discounted at 5% annually [29]. Base case analyses were
performed using Markov cohort simulation; second order
probabilistic sensitivity analysis was used to derive 95% confidence
intervals around mean costs and QALYs, and for probabilistic
sensitivity analysis (see below). First order Monte Carlo simulation
was used to estimate CRC incidence and death rates and the
number of primary screening tests and colonoscopies required.
Incremental analyses (expressed as the cost per QALY gained)
were performed by rank ordering all competing strategies by
increasing cost after eliminating strategies that were more costly
and less effective (i.e., dominated).
Model Validation
Consistent with guidelines for good modeling in health care
[30], the validity of our model was formally established including
extensive ‘‘debugging’’ exercises and calibration to published
clinical datasets [9–11]. Gastroenterologists, including two of the
authors (SJH and RJH), carefully reviewed the structure and flow
of the model. The model was also reviewed by Alaa Rostom,
Gastroenterologist and Medical Director at the Forzani and
MacPhail Colon Cancer Screening Centre in Calgary, Alberta.
Ultimately, it was determined that the model had good face
validity. After ensuring that there were no syntactical errors, we
first calibrated the model’s no screening arm against the no
screening control arms of the landmark FOBT RCTs [9–11]. For
this we used baseline adenoma and CRC prevalence rates from a
contemporary meta-analysis [31] and ensured that the number of
cancers and cancer deaths generated by our model closely
approximated the control arms of the clinical trials over an
identical follow-up period. We next ensured that the number of
cancers and cancer deaths predicted by the FOBT screening arms
closely approximated those noted within the FOBT arms of the
FOBT RCTs. All of the other strategies were validated in a similar
fashion assuring face validity and calibration. Finally, we also
compared our CRC and CRC death rate with those generated by
another validated decision analytical model, noting near perfect
correlation [32].
Computer Simulation Model
The Markov model was constructed using decision analysis
software (TreeAge Pro Suite 2007). It was assumed that all CRCs
arise through the following sequence: normal colon R nonadvanced
Economics of Colorectal Cancer Screening
PLoS Medicine | www.plosmedicine.org 2 November 2010 | Volume 7 | Issue 11 | e1000370adenoma R advanced adenoma R CRC. Nonadvanced adenomas
were defined as tubular adenomas ,10 mm in size. Advanced
adenomascomprised anyadenoma $10 mmregardlessof histology,
and adenomas ,10 mm containing at least 25% villous component
and/or high grade dysplasia. We considered several general health
states, including (1) alive with no prevalent or prior history of
adenomas or CRC, (2) alive with a missed adenoma, (3) alive with a
missed asymptomatic CRC, (4) alive with a missed CRC after
presenting with symptoms, (5) alive with a CRC found by screening,
(6) alive postpolypectomy, and (7) dead. Eachyear (1-y cycle length),
individuals with or without adenomas or CRC could either remain
in the same health state, progress to another health state, or die
(Figure 1).
In the base case, screening was offered annually for FOBT and
FIT, every 3 y for fecal DNA, every 5 y for flexible sigmoidoscopy
and CTC, and every 10 y for colonoscopy. Once a patient was
diagnosed with either an adenoma or CRC, the model’s design
permitted subsequent surveillance with colonoscopy at either 3- or
5-y intervals depending on the results of the last colonoscopy,
consistent with current guidelines [4–6]. Screening and surveil-
lance commenced at age 50 and stopped at age 75.
Data Inputs
Risk of polyps and CRC and the adenoma-carcinoma
sequence. We based our prevalence estimates of adenomatous
polyps and CRC on a recent systematic review among those at
average risk for CRC [31]. Age was determined to be an
important source of heterogeneity in the pooled estimates [31],
and thus the prevalence rates in our model were stratified into two
age categories: 50–64 and 65–75 y (Table 1).
Not all polyps are adenomatous. However, determining a
polyp’s histology generally requires that it be biopsied or removed.
As a result, some polypectomies expose patients to complications
without reducing the risk of CRC. We estimated that 41% [33] of
polyps ,10 mm were adenomatous compared to 82% of polyps
$10 mm (Table 1) [16]. Screening guidelines recommend that all
polyps be removed at the time of a colonoscopy to determine
histology and establish an appropriate surveillance interval.
Although some advocate for ignoring polyps ,5 mm in size
found on CTC, we assumed that all patients with polyps found on
CTC regardless of size would be referred for colonoscopy. The risk
of proximal adenomatous polyps and CRC is increased among
those with adenomatous polyps in the left colon [34]. As such, we
assumed that patients with left-sided adenomas found on flexible
sigmoidoscopy would be referred for colonoscopy consistent with
general clinical practice.
The rate of progression of adenomatous polyps is not well
established. We initially chose progression rates that were
consistent with other published models [32], and made small
adjustments to these rates to ensure that the total number of CRCs
in our natural history/no screening strategy closely approximated
the number of CRCs found in the control arms of the FOBT trials
[27].
Mortality. Death occurred according to either age-
dependent population mortality rates observed for Canadians
[35] or based on the mortality rates observed for patients with
CRC according to their stage at diagnosis (Table 1) [36]. Those
with CRC found through screening were assumed to have
improved survival over patients presenting with symptomatic
cancer, on the basis of a more favorable stage distribution (i.e.,
more early stage cancers) at diagnosis (Table 1).
Screening adherence. Adherence is important to the overall
effectiveness of a screening program. Even in a randomized trial
comparing annual FOBT with no screening, only 68% of patients
who were randomized to FOBT actually completed the initial
screen and 63% were compliant with subsequent rescreening.
Moreover, for patients with positive FOBT results, only 81% had
a colonoscopy [11]. We adopted these imperfect adherence rates
and assumed in the base case that adherence would be the same
across strategies (Table 1).
Test performance characteristics of the CRC screening
strategies. The only method for properly assessing the test
performance of a given screening modality is to compare it with a
reference standard in all cases. Although colonoscopy is not
infallible [7], it remains the accepted gold standard for evaluating
the entire colon. Therefore, the base case sensitivities and
specificities for polyps and CRC for each of the screening
modalities were taken from the literature following a thorough
search for properly designed studies that included at least a full
colonoscopy in all individuals (Table 2). For the stool-based tests
and for CTC, the test performance characteristics were considered
on a per person basis.
Stool-based tests. Given significant differences even
between the alternative stool-based screening tests themselves
(often due to different collection methods or assay types), it would
not be appropriate to consider them as a class [37]. As such, we
modeled different test performance scenarios for each test. A low
[38] and high [14] performance level was modeled for FOBT tests
that have reported in the literature (FOBT-low and FOBT-high,
respectively) and a low [39,40], mid [41], and high [42]
performance level was modeled for FIT assays that have been
reported in the literature (FIT-low, FIT-mid, and FIT-high,
respectively). The intent of modeling different levels of test
performance for FOBT and FIT was to represent the range
reported in the literature. This range is greatest for FIT, likely due
to differences in collection methods and assays (Table 2). FIT-low
represents that reported by Morikawa et al. [39,40] who studied
the Magstream system with 1 d of stool collection. FIT-mid
represents that reported by Nakama et al. [41] who used a 2-d
method with the Monohaem system. FIT-high represents that
reported by Levi et al. [42] who used the FlexSure OBT
technology following 3 d of fecal collection. Both the first- [38]
and second- [14] generation fecal DNA assays were modeled
(FDNA-SDT1 and FDNA-SDT2, respectively).
Flexible sigmoidoscopy. Flexible sigmoidoscopy can
evaluate the left colon to the splenic flexure, although this is not
always possible [43]. Routine clinical practice is generally to
perform a full colonoscopy in individuals found to have an
Figure 1. Model bubble diagram. This diagram depicts the general
health states and flow through the model.
doi:10.1371/journal.pmed.1000370.g001
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Variable Values Range References
Age-dependent variables
50- to 64-y-old individuals
Prevalence of nonadvanced adenomas 0.171 (0.10–0.25) [31]
Prevalence of advanced adenomas 0.038 (0.02–0.05) [31]
Prevalence of CRC 0.001 (0.0005–0.002) [31]
Annual death risk 0.005 — [35]
65- to 75-y-old individuals
Prevalence of nonadvanced adenomas 0.173 (0.10–0.25) [31]
Prevalence of advanced adenomas 0.082 (0.05–0.10) [31]
Prevalence of CRC 0.007 (0.002–0.01) [31]
Annual death risk 0.018 — [35]
Age-independent variables
Probability of annual transition from:
No polyp to nonadvanced adenoma – no history adenoma/CRC 0.02 (0.01–0.03) [32]
a
No polyp to nonadvanced adenoma – history adenoma/CRC 0.038 (0.03–0.05) [32]
a
Nonadvanced to advanced adenoma 0.019 (0.01–0.03) [32]
a
Advanced adenoma to CRC 0.048 (0.03–0.07) [32]
a
CRC 5-y mortality rates
Stage I 0.068 — [36]
Stage II 0.175 — [36]
Stage III 0.405 — [36]
Stage IV 0.919 — [36]
CRC stage distributions
In unscreened patients who develop CRC, the proportion with:
Stage I 0.145 (0.12–0.25) [9–11]
Stage II 0.356 (0.34–0.39) [9–11]
Stage III 0.280 (0.23–0.32) [9–11]
Stage IV 0.219 (0.18–0.25) [9–11]
In patients who have CRC found using FIT, FOBT, and FDNA, the proportion with:
Stage I 0.305 (0.29–0.33) [9–11]
Stage II 0.318 (0.30–0.35) [9–11]
Stage III 0.243 (0.20–0.26) [9–11]
Stage IV 0.134 (0.10–0.15) [9–11]
In patients who have CRC found using colonoscopy, CTC, and flex sig, the proportion with:
Stage I 0.425 (0.41–0.50) [38,46,68]
Stage II 0.226 (0.22–0.26) [38,46,68]
Stage III 0.267 (0.20–0.27) [38,46,68]
Stage IV 0.082 (0.0–0.09) [38,46,68]
Screening adherence rates (all strategies)
1st screen 0.68 (0.30–0.80) [9–11]
Subsequent screens 0.63 (0.10–0.80) [9–11]
Probability of colonoscopy after positive CTC, FOBT, FIT, FDNA, or flex sig 0.81 (0.60–0.90) [11]
Risk of bleeding
Colonoscopy, diagnostic 0.0003 (0.0–0.009) [69,70]
Colonoscopy, therapeutic 0.005 (0.003–0.015) [69–72]
Risk of perforation
Colonoscopy, diagnostic 0.0009 (0.0005–0.002) [70,73]
Colonoscopy, therapeutic 0.0024 (0.001–0.005) [70,73]
Flexible sigmoidoscopy 0.0002 (0.0001–0.0004) [32]
Risk of death after endoscopic perforation 0.049 (0.01–0.15) [74]
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sensitivity of flexible sigmoidoscopy includes the additional
lesions found by colonoscopy in patients identified as having an
adenoma on flexible sigmoidoscopy [44–46].
CTC and colonoscopy. Landmark studies [16,18] that
employed segmental unblinding methodology [47] provided the
base case test performance estimates for both CTC and
colonoscopy when possible. The sensitivity and specificity of
CTC for polyps $10 mm was taken from the National CT
Colonography Trial of the American College of Radiology
Imaging Network (ACRIN) [16], a large multicenter study of
CTC among primarily average-risk individuals. Polyps ,5m m
were not reported in this study or other large cohorts of average
risk individuals. However, we optimistically assumed that the
sensitivity reported for 6–9 mm polyps would be the same for all
polyps ,10 mm. In a sensitivity analysis we reduced the sensitivity
of polyps ,10 mm to that reported in a meta-analysis of CTC that
included higher risk patients [48]. The sensitivity of colonoscopy
for polyps $10 mm was taken from the study of Pickhardt et al.
[18], which reported the test performance of both CTC and
colonoscopy based on segmental unblinding. As this study also did
not report data for polyps ,5 mm, the sensitivity of colonoscopy
for polyps ,10 mm was taken from two back-to-back colonoscopy
studies (Table 2) [49,50].
Screening-related risks. Flexible sigmoidoscopy and
colonoscopy are associated with risks including bleeding,
perforation, and rarely, death (Table 1). Even though CTC is
less invasive than colonoscopy, colonic perforations have been
reported [51–53], though many of the small CTC induced
perforations diagnosed with the CT in asymptomatic individuals
may not be clinically important. We assumed a low risk of CTC-
induced perforation in the base case analysis [51,52], and that this
would never result in death (Table 1).
Costs. Costs related to screening. All costs are reported
in 2008 CAN$. The direct costs of flexible sigmoidoscopy and
colo-
noscopy, as well as costs attributed to bleeding and perforation
complications [54], were based on local estimates derived from the
Calgary Health Region costing database [55] and included the
nonphysician costs (capital, nursing, drugs, and cleaning costs) and
the physician fees for the procedure (Table 3). CTC for primary
CRC screening is not currently part of the schedule of medical
benefits in any province in Canada. The direct costs of CTC were
therefore conservatively assumed to be the same as that of a CT
abdomen/pelvis, likely an underestimate (Table 3). We assumed
that stool-based screening would be offered at a person’s annual
visit to their general practitioner, and as such, we only considered
the cost of the screening kit and related laboratory/processing
costs (Table 3).
For all screening modalities, we included the relevant patient 6
caregiver time and travel costs (nonmedical costs), on the basis of
available surveys for flexible sigmoidoscopy, colonoscopy, FOBT,
and CTC (Table 3) [8,56,57]. The nonmedical costs of FIT and
fecal DNA were assumed to be the same as FOBT. In the base
Table 2. Base case test performance characteristics for the screening modalities.
Screening Modality Sensitivity Specificity
Nonadvanced Adenoma Advanced Adenoma Cancer
FOBT-low [38] 0.052 0.107 0.129 0.952
FOBT-high [14] 0.030 0.074 0.500 0.980
FIT-low [39,40] 0.07 0.224 0.660 0.950
FIT-mid [41] 0.180 0.540 0.810 0.960
FIT-high [42] 0.180 0.610 0.940 0.910
Colonoscopy [18,49,50,75] 0.850 0.875 0.966 1.000
Colonoscopy after positive CTC 0.900 0.970 0.99 1.000
CTC [16] 0.760 0.900 0.966 0.890
Flexible sigmoidoscopy [44,45,46] 0.650 0.750 0.750 1.000
FDNA-SDT2 [14] 0.040 0.447 0.580 0.840
FDNA-SDT1 [38] 0.076 0.151 0.516 0.944
doi:10.1371/journal.pmed.1000370.t002
Variable Values Range References
Patient utility
No CRC 0.91 — [63]
Early CRC 0.74 — [63]
Advanced CRC 0.46 — [63]
Discount rate 0.05 — [29]
aMinor adjustments were applied to the rates used in the US Multi-Society Task Force model [32] such that the total of our baseline prevalence of CRC plus the number
of new CRCs developing in our natural history arm closely approximated the number of CRCs observed in the control arms of the FOBT RCTs [9–11].
doi:10.1371/journal.pmed.1000370.t001
Table 1. Cont.
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administering a screening program and thus assumed that
screening would be opportunistic in all strategies.
Costs related to managing CRC. Existing published data
on the total costs of managing patients with CRC are outdated.
We assumed that the cost of surgery for CRC has remained
relatively stable and thus based our surgical costs on a Canadian
study reporting 1998 figures, inflation adjusted to 2008 dollars
[58].
In contrast, the cost of treating CRC with chemotherapy has
increased substantially because of the development of more
expensive agents [22]. To estimate the cost of chemotherapy
provided for advanced CRC, we used data from the Canadian
Inter-Provincial Joint Oncology Drug Review (JODR) Process
[59]. These estimates were the average stage-based treatment costs
for chemotherapy, taking into account that not all patients would
be eligible for or would comply with treatment. Patients with stage
IIB disease (,50% of stage II patients) are generally managed with
adjuvant chemotherapy using eight cycles of capecitabine [60,61].
First line therapy for patients with stage III CRC was assumed to
be 6 mo of oxaliplatin-based therapy [62]. Considering the most
recent clinical trials and assumed standards of care, the average
patient with stage IV CRC received approximately 10 mo of
infusional fluorouracil (5-FU), leucovorin, and oxaliplatin (FOL-
FOX) in combination with bevacizumab, followed by 14 doses of
infusional 5-FU, leucovorin, and irinotecan (FOLFIRI). Those
lacking K-Ras mutations were assumed to go on to receive 4 mo of
anti-epidermal growth factor receptor–based inhibition therapy.
We did not include the potential costs of liver metastectomy
among stage IV patients, or the cost of preoperative radiation
therapy in patients with operable rectal cancer.
Valuing health benefits. Health benefits were measured in
terms of QALYs gained. We obtained utilities for relevant health
states on the basis of a study that used a standard gamble exercise
in patients with a previous history of CRC or polyps who were
presented with stage-dependent outcome states for CRC (Table 1)
[63].
Sensitivity Analysis
Allowance for uncertainty in the base case polyp and CRC
prevalence estimates, mortality assumptions, screening test per-
formance characteristics, screening-related risks, and costs were
considered through the use of univariate and probabilistic
sensitivity analyses. A number of scenario analyses were also
included. We considered a scenario in which the additional costs
of biologic chemotherapies for advanced stage CRC were
excluded. We also examined scenarios where FIT was offered
every 2 y instead of annually and analyzed our results without
nonmedical costs. We assessed the impact of differential adherence
rates across strategies at the initial screening encounter. For this
analysis, we used the adherence rates determined by Hol et al. in a
RCT comparing participation rates of FOBT, FIT, and flexible
sigmoidoscopy in a screening population [13]. As Hol et al. [13]
did not study fecal DNA, colonoscopy, or CTC, we assumed that
fecal DNA would have the same adherence as FIT due to its
comparable simplicity for patients, and we assumed that
Table 3. Base case direct health care costs and nonmedical costs and ranges considered.
Variable Values CAN$ Range CAN$ References
FOBT
a 12 6–18 [27]
FIT 19 10–30 [76]
Colonoscopy, diagnostic
b 857 500–1,200 [27]
Colonoscopy, therapeutic
c 999 700–1,700 [27]
CTC 582 440–730 [27]
FDNA 336 200–500 [25]
Flex sig 650 400–900 Determined locally
Bleeding complication 3,194 (2,400–4,000) [54]
Perforation complication 31,223 (23,500–39,000) [54]
Total cost of managing CRC Determined locally and [58–62]
Stage I CRC 25,049 —
Stage II CRC 36,143 —
Stage III CRC 96,768 —
Stage IV CRC 134,014 —
Nonmedical
d [8,56,57,77]
FOBT 36 (25–50)
FIT 36 (25–50)
FDNA 36 (25–50)
Colonoscopy 308 (200–450)
CTC 105 (100–200)
Flex sig 105 (100–200)
aFOBT: includes cost of FOBT kit (CAN$5), processing (CAN$7).
bDiagnostic colonoscopy: includes physician cost of diagnostic colonoscopy (CAN$327), and nonphysician cost of colonoscopy (CAN$530).
cTherapeutic colonoscopy: includes physician cost of therapeutic colonoscopy (CAN$401), and nonphysician cost of therapeutic colonoscopy (CAN$598).
dIncludes patient 6 caregiver time and travel costs, but excludes productivity losses [29].
doi:10.1371/journal.pmed.1000370.t003
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oscopy. We also assessed the impact of lower subsequent
adherence for the annual stool-based tests, since screening
noncompliance may be more prevalent with an annual test
compared to one offered less frequently. To do this assessment, we
examined scenarios with decreased FOBT and FIT follow-up
adherence.
Because we did not include any administrative costs for any of
the CRC screening programs, we performed a sensitivity analysis
to assess the impact of including administrative costs for the
various screening tests. We were unable to identify a document
that has reported the setup and operating costs for a population-
based CRC screening program, but it is possible that programs
that screen annually (i.e., stool-based tests) might have higher
administrative costs than ones that screen patients every 10 y (i.e.,
colonoscopy). We provide sensitivity analyses varying the admin-
istrative costs per screening test between CAN$10 and CAN$50 to
determine the impact on the results, making the assumption that
programs screening more frequently will incur higher administra-
tive costs.
To address limitations in classic univariate sensitivity analysis,
we also performed probabilistic sensitivity analysis, which allows
for the simultaneous sensitivity analysis of all variables over their
plausible range [64,65]. It does so by replacing estimates of
probabilities, utilities, and costs with specific probability distribu-
tions, which are based on the reported means and variances for
each variable. Statistical distributions were created around all of
the variables for which there was substantial measurement
uncertainty, including use of a beta distribution for proportions
(i.e., mortality, proportion of patients with Stage I, II, III, and IV
cancer), use of a normal distribution for normally distributed
variables (i.e., certain costs and utility measures), log-normal
distribution for skewed variables (i.e., certain costs), and triangular
distributions for variables with a range, but no statistical
distribution (i.e., adenoma transition over time, probability of
adherence). Given that sensitivity and specificity are linked
variables that do not vary independently (linked via receiver
operating curves that were unavailable), these variables were not
included within the probabilistic analyses—as noted above, the
sensitivity and specificity of the various screening tests were
subjected to wide sensitivity analysis using the testing character-
istics provided by different primary studies.
Results
Base Case Analysis
Annual CRC screening using FIT, assuming mid-range test
performance characteristics, was the preferred strategy for average
risk individuals in the base case analysis (Table 4). It was more
effective and less costly than almost all of the other strategies
including no screening. Only FIT when assuming even better test
performance characteristics (i.e., FIT-high) produced more
QALYs and resulted in fewer CRCs than FIT-mid, but at an
additional cost of CAN$85,150 per QALY gained.
Using base case estimates, over the lifetimes of a 100,000 patient
cohort, 4,857 and 1,782 individuals would develop and die from
CRC, respectively, if CRC screening was not undertaken (Table 5).
This ‘‘no screening’’ strategy would be expected to cost an average
of CAN$1,901 per patient. Annual screening with FIT-mid would
reduce the overall number of cancers by 71% and CRC mortality
by 74% while saving CAN$68 per patient. Compared with the
most effective FOBT strategy, FIT-mid would be expected to
reduce the number of cancers by 60%, and CRC mortality by
63%, while saving CAN$362 per person.
Sensitivity Analysis
Under no circumstances did flexible sigmoidoscopy, FOBT,
CTC, or fecal DNA appear attractive in comparison to other
CRC screening modalities. As such, these strategies are not
reported in our sensitivity analysis table (Table 6). Lowering the
cost of CRC treatment by excluding the use of biologic
chemotherapies resulted in a scenario where FIT-mid resulted in
additional costs compared to no screening (CAN$163 per patient
or CAN$3,691 per QALY gained). Increasing the cost of FIT
testing by 50% had a similar effect; FIT-mid cost an additional
CAN$105 per patient and was associated with a cost per QALY of
CAN$2,375 compared to no screening. Biennial screening using
FIT-mid increased the cost savings when compared to no
screening. However, performing FIT less frequently also made it
less effective.
When the initial adherence rates for each of the strategies was
no longer assumed to be identical, FIT-mid remained dominant
over no screening (Table 6). Assuming the base case initial
adherence rates, when we dropped the adherence rates for
subsequent screens for all of the annual fecal-based strategies, FIT-
mid remained dominant over no screening. However, when
subsequent adherence for FIT was dropped from 63% to 40%,
both FIT-mid and FIT-high became dominant over no screening,
and colonoscopy became the most effective strategy at a cost per
QALY gained of CAN$300,609 compared to FIT-high. When
subsequent adherence for FIT was decreased to only 20%,
colonoscopy remained the most effective strategy, at a cost per
QALY gained of CAN$32,912 compared to FIT-high (Table 6).
Finally, we performed a sensitivity analysis to assess the impact
of higher administrative costs that might be associated with an
annual screening program (i.e., FIT) compared to one offered less
frequently (i.e., colonoscopy). We noted that FIT remained
dominant over no screening unless the administrative costs were
,CAN$10 per test. If administrative costs were CAN$30 per test,
annual FIT was associated with a cost per QALY of CAN$3,120
compared with no screening. However, if the administrative costs
were CAN$50 per test, then colonoscopy would be the preferred
screening modality compared with FIT, and would be associated
with a cost per QALY gained of CAN$5,903 compared with no
screening.
Our probabilistic sensitivity analysis revealed that FIT-mid was
cost saving and more effective compared with no screening in
nearly 100% of the simulations performed, confirming the
robustness of the results (Figure 2).
Discussion
Our study demonstrates that annual screening with FIT,
assuming mid-range test performance characteristics, is more
effective and less costly than other CRC screening strategies,
including the most commonly used stool-based CRC screening
test, FOBT, and no screening. Among a cohort of 100,000 average
risk individuals followed until death, 4,857 cancers and 1,782
cancer-related deaths would be expected with no screening. An
annual FIT with high sensitivity for cancer (81%) and moderate
sensitivity for advanced adenomas (54%) [41] could reduce costs
and decrease the number of CRCs and cancer-related deaths to
1,393 and 457, respectively. Screening with FIT was also more
effective at reducing cancer and cancer-related deaths at lower
costs compared with FOBT.
FIT represents a significant advance over the traditional guaiac-
based FOBTs, in large part due to FITs improved sensitivity for
identifying adenomatous polyps. Our findings underscore the
importance of identifying patients with advanced adenomas and
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precancerous polyps. Indeed, changing the sensitivity of FIT for
cancer had relatively little impact on our results, whereas reducing
the sensitivity of FIT for advanced adenomas from 54% to below
45% resulted in FIT no longer being cost saving compared with no
screening.
Although it may seem counter-intuitive that screening with FIT
could be even more effective than colonoscopy, this is due to the
more frequent screening interval with FIT. In base case analyses,
and consistent with current guidelines [3,6], screening with FIT
was done annually compared to every 10 y with colonoscopy.
Therefore, even though the test performance of a single FIT test
was inferior to colonoscopy, there were more opportunities to
identify previously missed pathology with FIT compared to
colonoscopy.
Our results are robust. FIT with mid-range performance (FIT-
mid) remained optimal compared with no screening and all the
other strategies except FIT with even better test performance
(FIT-high) unless the cost of CRC treatment was reduced, or the
sensitivity for advanced adenomas was decreased significantly.
However, even with lower CRC treatment costs, FIT remained
economically attractive. Many health jurisdictions now fund
biologic chemotherapies for advanced-stage CRC and with further
advances in CRC chemotherapy, it is unlikely that management
costs for CRC will decrease [22]. In addition, our modeled CRC
treatment costs were lower than those used in a recent US study
that had similar results [25], lending further support to the notion
that CRC screening can indeed save money.
It is possible that the administrative costs of annual screening
programs such as FIT would be more expensive over the long-run
compared with those offered every 5 or 10 y. As these data are not
known, we did not consider administrative costs or the costs to build
and staff additional screening centers in our primary analysis.
However, in sensitivity analysis, we noted that FIT-mid remained
cost saving if the administration costs were ,CAN$10 per test, and
remained attractive compared with colonoscopy even if the
administrative costs per test were CAN$30 per test. It should also
be noted that the additional infrastructure required to implement
primary screening with CTC, flexible sigmoidoscopy, or colonos-
copy would likely counterbalance a substantial portion of these
additional administrative costs of an annual screening program.
We assumed in the base case that adherence would be identical
across all of the CRC screening strategies. Although this may not
be true, we are unaware of a study that has evaluated screening
uptake for all of the strategies we considered. However, fecal-based
screening does not require a bowel preparation, is associated with
lower patient-borne costs, and is safe to perform, which may be
more appealing to the general population. Furthermore, FIT does
not require any dietary restrictions. Indeed, in a recent
randomized trial, FIT was associated with higher screening uptake
than flexible sigmoidoscopy and FOBT [13]. Of course, this
finding only strengthens our conclusions as illustrated in our
scenario analysis in which FIT had relatively higher adherence
than all of the other strategies (Table 6). Recent data suggest that
screening adherence with FOBT may drop by 50% after only 2 y
in a biennial screening program [66]; this may affect programs
with frequent screening (i.e., annual fecal-based strategies) to a
greater extent than programs requiring less frequent screening
(i.e., colonoscopy). As expected, when we dropped our subsequent
adherence rates for FOBT and FIT, FIT-mid became less
effective, though it remained dominant compared with no
screening. In contrast, colonoscopy became the most effective
strategy when the subsequent adherence rates for FOBT and FIT
were dropped from 63% to 40%, though it was associated with an
unattractive incremental cost per QALY. It is clear that further
information on long-term adherence rates for annual stool-based
tests are needed.
Our study has limitations. As with most economic evaluations,
our results are limited by available evidence. The natural history of
adenomas and their progression to cancer is not clearly known.
However, we populated our model with the best available
evidence including a systematic review of adenoma and CRC
prevalence rates [31] and modeled new adenoma growth and
adenoma progression over time to closely match high quality
clinical datasets [9–11]. We did not model cancers arising from
lesions other than adenomas. However, most CRCs arising in
average risk individuals are believed to develop via the traditional
adenoma-carcinoma sequence. A small proportion of CRC may
develop from undetectable lesions (i.e., flat or depressed
adenomas), and it is known that some interval cancers can arise
through a rapid adenoma-carcinoma sequence between screening
studies [67]. It should be noted that this potential issue would
Table 5. Cancer outcomes and number of screening tests required during the lifetimes for a hypothetical 100,000 average risk
patient cohort.
Screening Test n Cancers Overall
a n Cancer Deaths
n Primary Screening
Tests n Colonoscopies
Cost Of Screening And
Managing CRC (CAN$)
FIT-high 1,290 432 819,178 56,541 2,004
FIT-mid 1,393 457 822,077 53,909 1,833
CTC 1,796 593 188,315 58,354 2,409
Colonoscopy 1,825 624 155,210 N/A 2,100
Flex Sig 2,036 699 189,135 49,484 2,263
FIT-low 2,634 918 871,986 31,597 2,005
FDNA-SDT2 3,129 1,143 331,090 20,805 2,491
FOBT-low 3,457 1,250 889,168 21,805 2,195
FOBT-high 3,890 1,368 902,299 15,089 2,084
FDNA-SDT1 4,131 1,530 331,699 14,548 2,720
No screening 4,857 1,782 n/a n/a 1,901
an cancers overall include symptomatic and screen found CRC.
doi:10.1371/journal.pmed.1000370.t005
Economics of Colorectal Cancer Screening
PLoS Medicine | www.plosmedicine.org 9 November 2010 | Volume 7 | Issue 11 | e1000370Table 6. Sensitivity analysis.
Screening Cost of Screening and Management (CAN$)
a QALY
Incremental Cost per QALY Gained
(CAN$)
a,b
Base case
FIT-mid 1,833 11.300
No screening 1,901 11.255 (Dominated)
c
FIT-high 2,004 11.302 84,876
Colonoscopy 2,100 11.296 (Dominated)
c
Lower stage III and IV cancer costs, including chemotherapy, but without biologics (Stage II CAN$35844, Stage III CAN$80,345, and stage IV
CAN$99,574)
No screening 1,582 11.255
FIT-mid 1,745 11.300 3,691
FIT-high 1,842 11.302 89,921
Colonoscopy 1,990 11.296 (Dominated)
c
Increase FIT direct cost by 50%
No screening 1,901 11.255
FIT-mid 2,006 11.300 2,375
Colonoscopy 2,100 11.296 (Dominated)
c
FIT-high 2,177 11.302 84,750
Biennial FIT screening (versus annual FIT screening modeled in baseline analyses)
FIT-mid 1,736 11.289
FIT-high 1,784 11.291 19,606
No screening 1,901 11.255 (Dominated)
c
Colonoscopy 2,100 11.296 64,741
Initial adherence 60% for FIT and fecal DNA, 50% for FOBT, 40% for CT colonoscopy, and 30% for colonoscopy [13]
FIT-mid 1,815 11.299
No screening 1,901 11.255 (Dominated)
c
FIT-high 1,986 11.301 85,927
Colonoscopy 2,055 11.279 (Dominated)
c
Decrease subsequent adherence rates for FITs and FOBTs from 63% to 40%
FIT-mid 1,751 11.293
FIT-high 1,839 11.295 38,536
No screening 1,901 11.255 (Dominated)
c
Colonoscopy 2,100 11.296 300,609
Decrease subsequent adherence rates for FITs and FOBTs from 63% to 20%
FIT-mid 1,752 11.283
FIT-high 1,772 11.286 8,709
No screening 1,901 11.255 (Dominated)
c
Colonoscopy 2,100 11.296 32,912
CAN$10 administrative cost added for all screening tests
No screening 1,901 11.255
FIT-mid 1,902 11.300 17
FIT-high 2,075 11.302 85,831
Colonoscopy 2,109 11.296 (Dominated)
c
CAN$50 administrative cost added for all screening tests
No screening 1,901 11.255
Colonoscopy 2,143 11.296 5,903
FIT-mid 2,176 11.300 10,202
FIT-high 2,357 11.302 89,651
aNumbers rounded to nearest CAN$1.
bEach incremental value compares the value of that strategy to next most costly, nondominated, strategy.
cDominated is defined as more costly and fewer QALYs compared with a comparator strategy.
doi:10.1371/journal.pmed.1000370.t006
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would be unlikely to impact the differential effectiveness between
our modeled strategies. Given data limitations, we modeled
identical CRC stage distributions for cancers detected using all
of the stool-based strategies despite differences in testing
characteristics. Given FIT’s superior sensitivity compared to
FOBT, patients diagnosed with CRC might be expected to have
more earlier stage cancers, which again would make FIT appear
more attractive. We assumed that the results of each screening test
were independent of the prior test result. While not informed by
evidence, it is possible that this is not entirely true; however, it is
important to note that the results of our analysis were robust to
small changes in the sensitivity and specificity of each of the
screening tests. Finally, although we did model the most widely
available and promising screening strategies, additional technol-
ogies are being developed and it is possible that other screening
paradigms, including nurse-based endoscopy, may become viable
in the future as a means to reduce the cost of delivering flexible
sigmoidoscopy and potentially colonoscopy.
In conclusion, annual screening with FIT having test perfor-
mance characteristics within the mid-range reported in the
literature is both more effective and less costly than other CRC
screening modalities, including FOBT and colonoscopy, and not
screening for CRC. Even if this level of test performance is not
attainable in clinical practice, annual screening with a lower
performing FIT is still highly attractive with a cost per QALY
gained of ,CAN$5,000 compared to no screening. Our results are
robust suggesting that screening for CRC with FIT should be
considered the modality of choice for average risk patients between
the ages of 50 and 75 in North America.
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Background. Colorectal (bowel) cancer is the second leading
cause of cancer deaths for both men and women in North
America.Colorectalcancerscreeningisanimportantmeansfor
reducing morbidity and mortality and fulfils the World Health
Organization criteria for mass screening. However, a variety
of CRC screening approaches are available. Colonoscopy is
viewedasthegoldstandardofcolorectalcancerscreeningasit
has a high sensitivity for identifying adenomas and cancer and
polyps can be removed during the screening examination.
However, colonoscopy is associated with a number of com-
plications and there are also barriers to access. Another type of
test, the guaiac fecal occult blood test, has been shown to
reduce mortality from colorectal cancer but this test has low
sensitivity for identifying colorectal neoplasia, particularly
adenomas. Fecal immunochemical tests, which also detect
blood in the stool, have improved test performance char-
acteristics (high sensitivity and specificity) and the potential to
improve participation rates compared to guaiac fecal occult
blood test and flexible sigmoidoscopy. Fecal DNA (a stool test,
based on the detection of DNA shed by cancerous tissue) is
another screening option, as is computed tomographic colono-
graphy (‘‘virtual’’ colonoscopy), that might rival colonoscopy in
detecting advanced adenomas and colorectal cancer but is
expensive and requires a full colonic preparation.
Why Was This Study Done? In the absence of firm com-
parative evidence to guide the selection of any one screening
modality and given the varied test performance characteristics
and the significant differences in costs and resources associated
with each, a robust cost-effectiveness analysis might help health
policy makers in deciding whether or not to offer screening
and if so, in selecting the most appropriate and cost effective
screening modality. In this study the researchers conducted
a full economic evaluation of all relevant colorectal cancer
screening modalities in North America.
What Did the Researchers Do and Find? The researchers
used an incremental cost-utility analysis, a sophisticated
modeling technique, and two hypothetical patient cohorts
(individuals with an ‘‘average risk,’’ i.e., no family history of
colorectal cancer, aged 50–64 and 65–75) to compare guaiac-
based fecal occult blood test or fecal immunochemical test
annually (the researchers considered three distinct fecal
immunochemical testing strategies on the basis of assays
and collection methods taken from studies that have reported
‘‘low,’’ ‘‘mid,’’ and ‘‘high’’ test performance characteristics),
fecal DNA every three years, flexible sigmoidoscopy or
computed tomographic colonography every 5 years, and
colonoscopy every 10 years. The researchers also included a
no screening natural history arm as a comparison to each
screening approach. For the baseline data of their model, the
researchers used adenoma and colorectal prevalence rates
from a recent systematic review and based screening
adherence, test performance, and colorectal treatment costs
on available data. The researchers found that annual fecal
immunochemical testing with mid-range testing character-
istics, was more effective and less costly compared to all
strategies (including no screening). Using this screening
modality, among the lifetimes of 100,000 average-risk patients,
the number of cancers could be reduced from 4,857 to 1,393
and the number of deaths from colorectal cancer from 1,782
to 457, while saving CAN$68 per person. Although in the
sensitivity and scenarioanalysis, screeningpatients using fecal
immunochemical testing became more expensive than a
strategy of no screening when the test performance of
fecal immunochemical testing was reduced, or the cost of
managing colorectal cancers was lowered, the researchers
found that screening for colorectal cancer with fecal
immunochemical testing remained the most economically
attractive screening option.
What Do These Findings Mean? This model-based
economic analysis found that fecal immunochemical testing
is more effective and less costly than all other colorectal
screening strategies, including the most commonly-used
stool-based screening test, guaiac-based fecal occult blood
testing, and no screening. Furthermore, this study suggests
that annual screening with fecal immunochemical testing
(assuming mid-range test performance characteristics)
reduces the risk of colorectal cancer and colorectal cancer–
related deaths, and lowers health care costs in comparison to
all other screening strategies and to no screening. Therefore,
health policy makers should consider prioritizing funding for
fecal immunochemical testing as the screening modality for
colorectal cancer.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000370.
N Cancer.org has information for patients on colorectal
cancer
N The US Centers for Disease Control (CDC) list colorectal
screening guidelines
N The CDC also provides patient information on colorectal
cancer Screening
Economics of Colorectal Cancer Screening
PLoS Medicine | www.plosmedicine.org 13 November 2010 | Volume 7 | Issue 11 | e1000370